Comparison of plasma exchange performances between Spectra Optia and COBE Spectra apheresis systems in repeated procedures considering variability and using specific statistical models

Plasma exchange for heparin‐induced thrombocytopenia in patients on extracorporeal circuits: A challenging case and a survey of the field

“…Choosing the appropriate type of vascular access is critical for safe and effective TPE . Continuous flow centrifugal apheresis platforms, such as the Spectra Optia Apheresis System which we use, typically utilize blood flow rates less than or equal to 100 mL/min . In contrast, the typical blood flow rate produced by a CentriMag pump for a patient on BiVAD support ranges between 4.1 and 6.5 L/min .…”

“…24 Continuous flow centrifugal apheresis platforms, such as the Spectra Optia Apheresis System which we use, typically utilize blood flow rates less than or equal to 100 mL/min. 22,44,45 In contrast, the typical blood flow rate produced by a CentriMag pump for a patient on BiVAD support ranges between 4.1 and 6.5 L/min. 46,47 We postulated that the substantial difference in flow rates and pressure between our patient's BiVAD circuitry and the apheresis machine could potentially promote the formation of air emboli.…”

Safety of acoustic separation in plastic devices for extracorporeal blood processing

“…We measured hematologic parameters based on measures that were tested in clinical studies of centrifugal apheresis devices . Those studies reported no statistically significant changes in coagulation activation when comparing pre‐procedure with post‐procedure measurements in patient blood.…”

“…Here, we applied acoustic frequency and energy relevant for plasmapheresis, causing cells to migrate toward the center of the channel (i.e., acoustic “focusing”), leaving a layer of plasma at the microchannel edges. Studies evaluating new apheresis devices typically include laboratory tests to detect RBC, platelet, and coagulation perturbations . We used those prior studies as a guide to clinically important laboratory tests for evaluating a novel acoustic apheresis microfluidic device.…”

Change of apheresis device decreased the incidence of severe acute graft‐versus‐host disease among patients after allogeneic stem cell transplantation with sibling donors

“…The devices differ in hardware and software aspects of PBSC collection. Key differences between Optia and Cobe are size difference in tubing, packing factors, manual adjustments required, and an elutriation step in the mononuclear cell (MNC) program of the Optia . These differences putatively create variations in, for example, PBSC graft composition, CD34+ cell concentration, and concentrations of nontargeted cells and platelets.…”